Shares of Caribou Biosciences Inc. (CRBU) are up over 120% at $5.51 in premarket trading on Monday, as the company gears up to report a slew of clinical trial data during a webcast at 8:00 a.m. ET today.
The company will report new data from its ANTLER Phase 1 trial evaluating vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
Caribou will also share first-in-human results from its phase 1 trial for CB-011, an allogeneic anti-BCMA CAR-T therapy targeting relapsed or refractory multiple myeloma, dubbed CaMMouflage, along with details on its anticipated pivotal phase 3 trial design for vispa-cel and next steps in advancing CB-011.
CRBU has traded in a range of $0.66 to $3.00 in the last 1 year. The stock closed Friday's trading at $2.42, up 4.31%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.